Montreal Heart Institute — Biomedical Watch V2

Traitements3programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
No prescriptionIn patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.	Maladie coronarienne	Phase 3	À vérifier	Canada	À vérifier
Prescription of AspirinIn patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.	Maladie coronarienne	Phase 3	À vérifier	Canada	À vérifier
Prescription of AspirinIn patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.	Maladie coronarienne	Phase 3	À vérifier	Canada	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Prescription of Aspirin	Maladie coronarienne	Phase 3	NCT07524335	ASCAD-P — Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.